Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nivolumab
Find trials that include:  Any drugs shown
Results 1-25 of 44 for your search:
Start Over
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-141, NCI-2014-01268, 2013-003622-86, NCT02105636
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
Phase: Phase III
Type: Treatment
Age: 15 and over
Trial IDs: CA209-238, NCI-2015-00460, 2014-002351-26, NCT02388906
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-142, NCI-2014-00793, 2013-003939-30, NCT02060188
Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA186-107, NCI-2014-02119, 2014-002241-22, NCT02253992
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA209-140, NCI-2014-01167, 2013-003645-42, NCT02038946
Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA209-205, NCI-2014-01773, 2014-001509-42, NCT02181738
Vaccine Therapy and Cyclophosphamide with or without Nivolumab in Treating Patients with Previously Treated Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J14113, NCI-2015-00233, ADU-CL-06, CA209-248, NCT02243371
Nivolumab in Treating Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY002, NCI-2014-02021, PNRG-GY002_A01PAMDREVW01, NCT02257528
Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients with Acute Myeloid Leukemia in Remission after Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CIRB 15-0185, NCI-2014-02167, P9706_R03PAPP01, 9706, NCT02275533
Nivolumab in Treating Patients with Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NCI9673, NCI-2014-02420, P9673_R03PAPPHOLD01, 9673, NCT02314169
Nivolumab in Treating Patients with Recurrent and/or Metastatic Nasopharyngeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1471, NCI-2014-02673, 9742, NCT02339558
Nivolumab in Treating Patients with Advanced Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-137, NCI-2015-00178, NCT02350764
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA209-275, NCI-2015-00650, NCT02387996
Nivolumab and Azacitidine in Treating Patients with Refractory/Relapsed Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0861, NCI-2015-00593, NCT02397720
Start Over